Valuation: Alzinova AB

Market Cap 204M 21.47M 18.61M 17.42M 15.89M 29.91M 2.05B 30.41M 80.03M 1.03B 80.62M 78.87M 3.42B P/E 2026 *
-3.73x
P/E 2027 * -2.65x
Enterprise Value 188M 19.79M 17.15M 16.06M 14.65M 27.57M 1.89B 28.03M 73.76M 945M 74.31M 72.69M 3.15B EV / Sales 2026 *
6.01x
EV / Sales 2027 * -
Free-Float
82.23%
Yield 2026 *
-
Yield 2027 * -
1 day-0.89%
1 week-2.82%
Current month-13.88%
1 month+38.75%
3 months+146.67%
6 months+35.37%
Current year+20.51%
1 week 0.95
Extreme 0.952
1.14
1 month 0.61
Extreme 0.61
1.23
Current year 0.38
Extreme 0.382
1.61
1 year 0.38
Extreme 0.382
2.28
3 years 0.38
Extreme 0.382
4.62
5 years 0.38
Extreme 0.382
8.7
10 years 0.38
Extreme 0.382
44.9
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2024
Chief Operating Officer 54 17/08/2011
Director of Finance/CFO 57 27/03/2024
Director TitleAgeSince
Director/Board Member 61 01/09/2015
Director/Board Member 69 01/01/2018
Director/Board Member - 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.89%-2.82%-20.84%-70.18% 21.47M
-1.53%+0.82%+3.66%+14.53% 49.54B
-0.69%+6.25%+492.36%+585.40% 44.06B
+0.08%+11.23%+23.99%+81.74% 40.85B
+0.76%+6.85%+35.40%+10.92% 40.14B
+4.73%+13.29%+27.76%+54.22% 34.17B
+0.51%+5.29%+34.62%+126.87% 16.9B
-0.41%+4.08% - - 16.78B
-0.49%-0.23%+4.10%+20.57% 14B
+1.81%+20.45%+89.35%+31.49% 13.46B
Average +0.36%+6.65%+76.71%+95.06% 26.99B
Weighted average by Cap. +0.36%+7.39%+106.93%+138.25%

Financials

2026 *2027 *
Net sales 31.35M 3.3M 2.86M 2.67M 2.44M 4.59M 314M 4.67M 12.28M 157M 12.37M 12.1M 525M -
Net income -3.2M -336K -292K -273K -249K -469K -32.08M -476K -1.25M -16.06M -1.26M -1.24M -53.58M -50.35M -5.29M -4.59M -4.29M -3.92M -7.37M -505M -7.5M -19.73M -253M -19.87M -19.44M -843M
Net Debt -16M -1.68M -1.46M -1.36M -1.25M -2.34M -160M -2.38M -6.27M -80.3M -6.32M -6.18M -268M -19M -2M -1.73M -1.62M -1.48M -2.78M -191M -2.83M -7.44M -95.35M -7.5M -7.34M -318M
Logo Alzinova AB
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Employees
7
Date Price Change Volume
12/08/26 SEK 0.9990 -0.89% 936,654
11/08/26 SEK 1.008 -1.18% 1,241,433
10/08/26 SEK 1.020 -4.14% 1,217,998
07/08/26 SEK 1.064 -1.48% 1,844,666
06/08/26 SEK 1.080 +5.06% 1,992,704

Annual profits - Rate of surprise